Australia News

Found 8,053 articles

• Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

  3/23/2023

  Enveric Biosciences, Inc. today announced that it has entered into an agreement with Avance Clinical for its planned Phase 1 clinical trial of EB-373, the company’s lead candidate targeting the treatment of anxiety disorders.

• Clear Medical Imaging and See-Mode Technologies Announce Partnership via CureLabs Innovation Hub

  3/23/2023

  Clear Medical Imaging announces partnership with See-Mode Technologies to adopt See-Mode, an artificial intelligence (AI) software application that increases efficiencies within the ultrasound workflow by assessing ultrasound images, automatically detecting clinical pathologies, and building a complete report.

• Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

  3/23/2023

  Immutep Limited today announces that new data evaluating eftilagimod alpha in combination with pembrolizumab from Part B of the TACTI-002 Phase II trial in 2nd line PD-X refractory non-small cell lung cancer (NSCLC) patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023 taking place in Copenhagen, Denmark and virtually from 29 March to 1 April 2023.

• EVOKE Presentation Awarded Overall Winner at ASIPP Annual Meeting

  3/22/2023

  Saluda Medical Pty Limited announced that the EVOKE 36-month Study received the Outstanding Achievement in Research Award at the 25th annual meeting of the American Society of Interventional Pain Physicians in National Harbor, MD.

• Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

  3/21/2023

  Enveric Biosciences today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic.

• Immunexpress to Present Data at ISICEM 2023 Indicating that SeptiCyte® RAPID Outperforms Other Rapid Measures for Sepsis Diagnosis

  3/21/2023

  Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today a poster presentation at the 2023 International Symposium on Intensive Care and Emergency Medicine.

• Carina Biotech to Present Preclinical Data Evaluating LGR5-Targeted CAR-T Cell Therapy in Colorectal Cancer Models at 2023 AACR

  3/21/2023

  Carina Biotech (Carina), a cell therapy immuno-oncology company, today announced four poster presentations from preclinical studies of its LGR5-targeting CAR-T platform in colorectal cancer at the 2023 American Association for Cancer Research (AACR) Annual Meeting that will take place in Orlando, Florida on April 14-19.

• SYMBYX announces promising Sydney Adventist Hospital clinical trial results for Parkinson's using the SYMBYX Neuro - a new light therapy wellness helmet

  3/17/2023

  SYMBYX today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects of a new red/infrared light therapy helmet on patients living with Parkinson's Disease.

• AVITA Medical Appoints New Non-Executive Member to the Board of Directors

  3/16/2023

  AVITA Medical, Inc. announced the appointment of Cary Vance to its Board of Directors, effective April 1, 2023.

• Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

  3/16/2023

  Alterity Therapeutics today announced the first participant has been dosed in the U.S. in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

• Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

  3/16/2023

  Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”) today announced that PRP exerts significant effects against chemoresistant pancreatic tumor cells, as reported by one of the Company’s joint researchers, Mrs. Belén Toledo Cutillas MSc, at the laboratory of Professor Macarena Perán, PhD, University of Jaén, Granada, Spain.

• Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

  3/14/2023

  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) today announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).

• Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

  3/14/2023

  Alterity Therapeutics today announced that the composition of matter patent previously allowed by the United States Patent and Trademark Office (USPTO) has now been granted.

• Intelligent Bio Solutions Inc. Selects HASTA Laboratory as Drug Testing Specialist in Australia

  3/13/2023

  Intelligent Bio Solutions Inc. today announced that the Company has selected Human and Supplement Testing Australia ("HASTA").

• Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)

  3/9/2023

  Bionomics Limited announced the release of a comprehensive analysis of the data from its Phase 2 PREVAIL study to evaluate the efficacy and safety of BNC210, a novel α7 nicotinic acetylcholine receptor negative allosteric modulator, for the acute treatment of Social Anxiety Disorder.

• Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

  3/8/2023

  Alterity Therapeutics today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

• Opthea Receives A$8.7 million R&D Tax Incentive

  3/7/2023

  Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received an A$8.7 million research and development tax credit from the Australian Taxation Office.

• Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference

  3/6/2023

  Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference being held virtually on March 13-15, 2023.

• Dr Ken Herrmann Appointed to RAD Scientific Advisory Board

  3/3/2023

  Radiopharm Theranostics, a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board.

• Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

  3/3/2023

  Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to announce that it has engaged Catalent (‘Catalent’) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development program and (2), potential wider commercial use.